Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent hemagglutinin nanoparticle influenza vaccine + Matrix-M adjuvant
- Development stage
- Discontinued
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The trivalent hemagglutinin nanoparticle influenza vaccine + Matrix-M adjuvant is a combination vaccine composed of recombinant nanoparticle-based hemagglutinin antigens from three distinct influenza virus strains, formulated with Matrix-M adjuvant. The Matrix-M adjuvant is a saponin-based nanoparticle adjuvant derived from Quillaja saponaria (soapbark) tree, mixed with cholesterol and phospholipids to form cage-like nanoparticles (Matrix-A and Matrix-C). This combination enhances both the magnitude and duration of the immune response to the vaccine antigens, promoting strong humoral (antibody) and cellular immunity, notably a Th1-dominant CD4+ response and cross-reactive antibodies. It is used primarily for prophylaxis against influenza, supporting stronger and broader immunity than traditional influenza vaccines, and may offer cross-protection against multiple strains[1][2][3].
- Brand names
- Novavax flu vaccine
- Other names
- Nano-Flutrivalent nanoparticle influenza vaccine
02
Targets
HA (Hemagglutinin)H3 HA (Influenza A hemagglutinin H3)
Beyond the preview
Go deeper on trivalent hemagglutinin nanoparticle influenza vaccine + Matrix-M adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent hemagglutinin nanoparticle influenza vaccine + Matrix-M adjuvant.